GRGuanghui Ren

Guanghui Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guanghui Ren has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Ying Zhu

    Department of Infectious Disease, Liver Disease Center of Integrated Traditional Chinese and Western Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

    2 shared publications
  • Guiqun Huang

    Department of Infectious Disease, Liver Disease Center of Integrated Traditional Chinese and Western Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

    1 shared publication
  • Jing Wang

    Department of Infectious Disease, Liver Disease Center of Integrated Traditional Chinese and Western Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

    1 shared publication
  • Kaining Jia

    Clinical Trials Center Huabei Petroleum Administration Bureau General Hospital Renqiu China

    1 shared publication
  • Lianxin Zhu

    Department of Infectious Disease, Liver Disease Center of Integrated Traditional Chinese and Western Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

    1 shared publication
  • Qingwei Cong

    Department of Infectious Disease, Liver Disease Center of Integrated Traditional Chinese and Western Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

    1 shared publication

Latest Publications

  • Hepatic Steatosis Inhibits Hepatitis B Virus Replication by Promoting miR ‐122‐5p‐ SOX4

    by Guanghui Ren, Kaining Jia, Sitong Yi, Shi Yin, Guiqun Huang, Ying Zhu

    The rising prevalence of chronic hepatitis B (CHB) and metabolic dysfunction–associated fatty liver disease (MAFLD) comorbidity necessitates a deeper understanding of their clinical interplay. Although miR‐122 is a known liver‐specific regulator of chronic liver diseases, its specific role in the context of CHB‐MAFLD remains elucidated. In this study, serum analysis revealed that CHB‐MAFLD patients exhibit significantly lower levels of HBV DNA, pgRNA, and HBsAg compared to patients with CHB alone, which correlated with elevated miR‐122 expression. Through bioinformatics and molecular assays, SOX4 was identified as a direct downstream target of miR‐122‐5p. Utilizing an HBV‐infected steatotic cell model, we observed that the comorbid state suppresses HBV replication markers—including DNA, pgRNA, HBsAg, and HBcrAg—while concurrently upregulating the miR‐122‐5p/SOX4 axis. Functional experiments demonstrated that miR‐122‐5p and SOX4 both act as inhibitors of HBV activity, as their knockdown enhanced viral replication, while their overexpression led to significant suppression. These findings suggest that the metabolic environment in CHB‐MAFLD may naturally suppress HBV replication through the activation of a novel miR‐122/SOX4 regulatory axis. This study highlights miR‐122 as a potential therapeutic target and provides a mechanistic basis for the altered viral kinetics observed in patients with dual liver pathology. Trial Registration: Chinese Clinical Trial Registry identifier: ChiCTR2200063555


  • Open Access

    Targeting Wnt3a and Loxl2 Synergistically Induces Ferroptosis in Liver Cancer Stem Cells and Suppresses Tumorigenesis

    by Guanghui Ren, Qingwei Cong, Jing Wang, Wenyue Gao, Yunpeng Guan, Lianxin Zhu, Ying Zhu

    Hepatocellular carcinoma (HCC) has a poor prognosis and high mortality. Ferroptosis, an iron‐dependent regulated cell death process, is implicated in cancer development and treatment. Wnt signaling and lysyl oxidase (Lox) family members are associated with ferroptosis. This study investigates how Wnt3a and/or Loxl2 knockdown affects liver cancer stem cells (LCSCs) and orthotopic tumor growth in mice, and explores the role of ferroptosis‐related genes. Bioinformatics identified ferroptosis‐ and HCC‐associated differentially expressed genes (DEGs) correlated with Wnt3a/Loxl2. LCSCs sorted from Hep3B were transduced with lentivirus for gene knockdown. Ferroptosis markers and DEG expression were analyzed. Wnt3a/Loxl2 knockout mice were generated using CRISPR‐Cas9, and orthotopic tumor models were established. Tumor inhibition rates, ferroptosis‐related indicators, and DEG expression were assessed. 199 ferroptosis‐related DEGs were identified in HCC; ZEB1 was selected as a key gene via PPI analysis. Wnt3a/Loxl2 knockdown increased Fe 2+ and MDA, and decreased GSH, most evidently in double‐knockdown cells. In vivo, single‐ and double‐knockout groups showed suppressed tumor growth, with inhibition rates of 51%, 71%, and 93%, respectively. Tumor tissues exhibited similar ferroptosis marker changes. ZEB1 was upregulated in both cellular and animal knockout models. Wnt3a/Loxl2 knockdown promotes ferroptosis in LCSCs and inhibits orthotopic tumor growth, with the strongest effect following dual‐gene knockout. ZEB1 may be an important regulatory factor in this process.